Maajo 19, 2022, Maamulka Alaabooyinka Caafimaadka Qaranka ee Shiinaha (NMPA) ayaa ansixiyay codsiga suuq-geynta ee Bayer's Vericiguat (2.5 mg, 5 mg, iyo 10 mg) ee hoos yimaada magaca astaanta Verquvo™.
Daawadan waxaa loo isticmaalaa bukaanada qaangaarka ah ee leh calaamadaha xanuunka wadnaha ee joogtada ah iyo hoos u dhigista jajabka ka saarista (jajabka jebinta <45%) kuwaas oo la dejiyo ka dib dhacdo dhawaan la'aan ah oo leh daawaynta xididka, si loo yareeyo khatarta isbitaal dhigga wadnaha wadnaha ama degdegga ah daaweynta diuretic xididka.
Oggolaanshaha Vericiguat waxay ku salaysan tahay natiijooyin wanaagsan oo ka soo baxay daraasadda VICTORIA, taas oo muujisay in Vericiguat ay sii yarayn karto khatarta buuxda ee dhimashada wadnaha iyo xididada isbitaallada wadnaha oo aan shaqeynin 4.2% (dhacdooyinka khatarta khatarta ah ee hoos u dhaca / 100 bukaan-sano) bukaanada qaba wadnaha guuldarada oo dhawaan dhacday dhacdo hoos u dhac ku ah wadna xanuunka oo ku xasilay daawaynta xididada iyada oo la yareeyey jajabka ka saarista (jajabka ka saarista <45%).
Janaayo 2021, Vericiguat waxaa lagu ansixiyey Maraykanka si loogu daaweeyo calaamadaha xanuunka wadnaha ee daba-dheeraada ee bukaanada leh jajab ka hooseeya 45% ka dib markii ay la kulmeen dhacdo wadnaha ah oo sii xumaanaysa.
Ogosto 2021, Codsiga cusub ee daroogada ee Vericiguat waxaa aqbashay CDE ka dibna lagu daray dib u eegista mudnaanta leh iyo habka ansixinta iyada oo loo eegayo "daawoyinka degdegga ah ee kiliinikada, daawooyinka cusub iyo daawooyinka cusub ee la hagaajiyey ee ka hortagga iyo daaweynta cudurrada faafa ee waaweyn iyo cudurrada naadirka ah" .
Abriil 2022, Xeerka 2022 AHA/ACC/HFSA ee Maaraynta Wadnaha Wadnaha, kaas oo ay si wada jir ah u soo saareen Kulliyada Wadnaha ee Maraykanka (ACC), Ururka Wadnaha ee Maraykanka (AHA), iyo Bulshada Wadnaha Wadnaha ee Ameerika (HFSA), oo la cusboonaysiiyay daawaynta farmashiyaha ee wadne hawlgabka oo leh jajabka saarista la dhimay (HFrEF) oo lagu daray Vericiguat dawooyinka loo isticmaalo daawaynta bukaanada qaba HFrEF khatarta sare leh iyo sii xumeynta wadnaha ee ku salaysan daaweynta caadiga ah.
Vericiguat waa kicinta sGC (guonylate cyclase ee milmi kara) oo leh hannaan cusub oo ay si wadajir ah u soo saareen Bayer iyo Merck Sharp & Dohme (MSD).Waxay si toos ah u faragelin kartaa cilladda habka calaamadaynta unugyada waxayna hagaajin kartaa dariiqa NO-sGC-cGMP.
Daraasadaha hore ee bukaan-socodka iyo bukaan-socodka ayaa muujiyay in NO-soluble guanylate cyclase (sGC) -cyclic guanosine monophosphate (cGMP) dariiqa calaamadaynta waa bartilmaameed suurtagal ah oo loogu talagalay horumarka wadnaha ee joogtada ah iyo daaweynta wadnaha oo aan shaqeynin.Marka la eego xaaladaha jir ahaaneed, dariiqan calaamaduhu waa dariiqa muhiimka ah ee nidaaminta makaanikada myocardial, shaqada wadnaha, iyo shaqada endothelial vascular.
Marka la eego xaaladaha pathophysiological ee wadnaha oo aan shaqeynin, bararka kordhay iyo cillad la'aanta xididdada xididada waxay yareeyaan NOV bioavailability iyo isku-darka hoose ee cGMP.Yaraanta cGMP waxay keenaysaa nidaam-la'aanta kacsanaanta xididdada xididada, xididada xididada iyo sclerosis, fibrosis iyo hypertrophy, iyo cillad la'aanta wadnaha iyo kelyaha ee microcirculatory, sidaas awgeed waxay sii kordhineysaa dhaawaca myocardial ee sii socda, bararka oo kordha iyo hoos u dhaca shaqada wadnaha iyo kelyaha.
Waqtiga boostada: Meey-19-2022